In this summary article published in the Expert Review of Vaccines, Sanofi Pasteur’s Bruno Guy, lead for Dengue Scientific Affairs and colleagues describe the main features and development of the dengue vaccine which has been recommended by the WHO for use in settings with high burden of disease and licensed by several dengue-endemic countries in Asia and Latin America for use in populations above 9 years of age. The article also outlines the long-term safety follow-up studies of the efficacy trials that are currently ongoing, and post-licensure studies that will evaluate the vaccine effectiveness and safety in ‘real-life’ following vaccine introduction.
Bruno Guy, Fernando Noriega, R. Leon Ochiai, Maïna L’azou, Valentine Delore, Anna Skipetrova, François Verdier, Laurent Coudeville, Stephen Savarino & Nicholas Jackson
Read the full article: A recombinant live attenuated tetravalent vaccine for the prevention of dengue – Expert Review of Vaccines Vol. 16 , Iss. 7,2017 – http://dx.doi.org/10.1080/14760584.2017.1335201